SCHEMBL4837487

SCHEMBL4837487

CC(N)c1nc2ccc(-c3c(-c4ccccc4)ncn3C3CCCCC3)cc2s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 0.41
MAPK13 O15264 2/20 0.41
MAPK12 P53778 2/20 0.41
MAPK11 Q15759 2/20 0.41
EGFR P00533 2/20 0.41
CSNK1D P48730 1/20 0.41
CSNK1E P49674 1/20 0.41
KCNH2 Q12809 1/20 0.41
TNIK Q9UKE5 1/20 0.38
ACVR1 Q04771 1/20 0.37
PIK3CA P42336 2/20 0.36
PI4KA P42356 2/20 0.36
PI4KB Q9UBF8 2/20 0.36
TGFBR1 P36897 3/20 0.35
TEK Q02763 1/20 0.35
LIPC P11150 2/20 0.35
LIPG Q9Y5X9 1/20 0.35
PIK3CD O00329 1/20 0.34
PIK3CB P42338 1/20 0.34
PIK3CG P48736 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4834028 0.86 PIK3CA (0.52) MAPK14MAPK13MAPK12MAPK11EGFR
SCHEMBL4838938 0.84 MAPK14 (0.41) MAPK14MAPK13MAPK12MAPK11EGFR
SCHEMBL4837492 0.82 MAPK14 (0.41) MAPK14MAPK13MAPK12MAPK11EGFR
SCHEMBL990284 0.76 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK11EGFR
SCHEMBL991427 0.75 MAPK14 (0.50) MAPK14MAPK13MAPK12MAPK11EGFR
SCHEMBL4837575 0.74 MAPK14 (0.72) MAPK14EGFRCSNK1DPI4KB
SCHEMBL990285 0.74 KDM4E (0.41) MAPK14MAPK13MAPK12MAPK11EGFR
SCHEMBL990252 0.74 SPHK1 (0.45) MAPK14MAPK13MAPK12MAPK11EGFR
SCHEMBL989412 0.71 MAPK14 (0.41) MAPK14MAPK13MAPK12MAPK11EGFR
SCHEMBL5748234 0.69 MAPK14 (0.60) MAPK14MAPK13MAPK12MAPK11EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320995-B2 Benzimidazoles and benzothiazoles as inhibitors of map kinase ELI LILLY AND COMPANY (US) 2008-01-22 US disclosed
EP-1554272-B1 BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE LILLY CO ELI (US) 2006-10-25 EP disclosed
US-20050272791-A1 Benzimidazoles and benzothiazoles as inhibitors of map kinase EIL LILLY AND COMPANY (US) 2005-12-08 US disclosed
EP-1554272-A1 BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE ELI LILLY AND COMPANY (US) 2005-07-20 EP disclosed
WO-2004014900-A1 BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE ELI LILLY AND COMPANY (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272791-A1 Benzimidazoles and benzothiazoles as inhibitors of map kinase MAP3K8, MAPK8, MAPK1 MAPK14 10/4885MAPK13 47/4885MAPK12 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.